Prostate Cancer Vaccine

WASHINGTON (AP) -- Federal health advisers are endorsing an experimental vaccine to treat prostate cancer.

The Food and Drug Administration adviser voted unanimously to declare Provenge as safe. And in a 13-4 vote, the panel agreed to call it effective for treating advanced cases of prostate cancer that no longer respond to hormone treatment.

The F-D-A is not bound to follow the judgment of its advisory committees, but it usually does. A final F-D-A decision is expected in May.

If it is approved, Provenge would become the third cancer vaccine and the first for therapeutic use. Vaccines against liver and cervical cancer are both preventive.

Provenge in made by Seattle-based Dendreon Corporation.

Prostate cancer is the second most common cancer in American men, after skin cancer.


Comments are posted from viewers like you and do not always reflect the views of this station.
powered by Disqus
23 WIFR 2523 North Meridian Road Rockford, IL. 61101 Business: 815-987-5300 Fax: 815-965-0981 News: 815-987-5330 Fax: 815-987-5333
Copyright © 2002-2014 - Designed by Gray Digital Media - Powered by Clickability 6778272 - wifr.com/a?a=6778272
Gray Television, Inc.